110 related articles for article (PubMed ID: 24980872)
1. Is charged particle therapy superior to photon therapy?
Koto M
Lancet Oncol; 2014 Aug; 15(9):918-9. PubMed ID: 24980872
[No Abstract] [Full Text] [Related]
2. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis.
Patel SH; Wang Z; Wong WW; Murad MH; Buckey CR; Mohammed K; Alahdab F; Altayar O; Nabhan M; Schild SE; Foote RL
Lancet Oncol; 2014 Aug; 15(9):1027-38. PubMed ID: 24980873
[TBL] [Abstract][Full Text] [Related]
3. [Brachytherapy of carcinoma of the tip of the nose. A new technique].
Rigon A; Cauzzo MC; Friso ML; Zorat PL; Zandonà R
Radiol Med; 1990 Nov; 80(5):734-6. PubMed ID: 2267395
[No Abstract] [Full Text] [Related]
4. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
Radiother Oncol; 2015 Mar; 114(3):289-95. PubMed ID: 25497556
[TBL] [Abstract][Full Text] [Related]
5. Calculations related to the possible use of photons, neutrons, negatively charged pions, protons, and alpha particles in radiotherapy.
Alsmiller RG; Santoro RT; Armstrong TW; Barish J; Chandler KC; Chapman GT
Radiat Res; 1974 Dec; 60(3):369-87. PubMed ID: 10881718
[No Abstract] [Full Text] [Related]
6. Outcome and toxicity profile after brachytherapy for squamous cell carcinoma of the nasal vestibule.
Lipman D; Verhoef LC; Takes RP; Kaanders JH; Janssens GO
Head Neck; 2015 Sep; 37(9):1297-303. PubMed ID: 24838690
[TBL] [Abstract][Full Text] [Related]
7. Interstitial photon radiation.
Chan DY; Solomon SB; Kavoussi LR
J Endourol; 2003 Oct; 17(8):641-5. PubMed ID: 14622484
[TBL] [Abstract][Full Text] [Related]
8. Collision-kerma conversion between dose-to-tissue and dose-to-water by photon energy-fluence corrections in low-energy brachytherapy.
Giménez-Alventosa V; Antunes PC; Vijande J; Ballester F; Pérez-Calatayud J; Andreo P
Phys Med Biol; 2017 Jan; 62(1):146-164. PubMed ID: 27991455
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma.
Bacorro W; Escande A; Temam S; Dumas I; Routier E; Gensse MC; Blanchard P; Janot F; Mateus C; Tao Y; Robert C; Deutsch E; Haie-Meder C; Chargari C
Brachytherapy; 2017; 16(5):1021-1027. PubMed ID: 28743612
[TBL] [Abstract][Full Text] [Related]
10. Interstitial high-dose-rate-brachytherapy in advanced esthesioneuroblastoma.
Tselis N; Heyd R; Baghi M; Zamboglou N
Laryngoscope; 2008 Nov; 118(11):2006-10. PubMed ID: 18641524
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of planocellular carcinoma of the nasal vestibule].
Evensen JF; Jacobsen AB; Tausjø J; Bøhler P
Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3197-200. PubMed ID: 9411856
[TBL] [Abstract][Full Text] [Related]
12. Brachytherapy in head and neck cancer: selection criteria and results at the University of Florida.
Mendenhall WM; Parsons JT; Mendenhall NP; Million RR
Oncology (Williston Park); 1991 Feb; 5(2):44-54; discussion 59-60. PubMed ID: 1826208
[No Abstract] [Full Text] [Related]
13. [A livid, painless lesion of the external nose in an elder man].
Schuppan SF; Ott I; Voith C; Baier G
Laryngorhinootologie; 2011 May; 90(5):296-7. PubMed ID: 21110293
[No Abstract] [Full Text] [Related]
14. Photon spectrometry for the determination of the dose-rate constant of low-energy photon-emitting brachytherapy sources.
Chen ZJ; Nath R
Med Phys; 2007 Apr; 34(4):1412-30. PubMed ID: 17500473
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
16. Retreatment of advanced esthesioneuroblastoma with high-activity I-125 endocurietherapy: a case report.
Kumar PP; Ogren FP; McComb RD; Jones EO; McCaul GF
J Natl Med Assoc; 1991 Aug; 83(8):735-8. PubMed ID: 1956087
[TBL] [Abstract][Full Text] [Related]
17. The difference of scoring dose to water or tissues in Monte Carlo dose calculations for low energy brachytherapy photon sources.
Landry G; Reniers B; Pignol JP; Beaulieu L; Verhaegen F
Med Phys; 2011 Mar; 38(3):1526-33. PubMed ID: 21520864
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of brachytherapy lung implant dose distributions from photon-emitting sources due to tissue heterogeneities.
Yang Y; Rivard MJ
Med Phys; 2011 Nov; 38(11):5857-62. PubMed ID: 22047349
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric prerequisites for routine clinical use of new low energy photon interstitial brachytherapy sources. Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee. Ad Hoc Subcommittee of the Radiation Therapy Committee.
Williamson J; Coursey BM; DeWerd LA; Hanson WF; Nath R
Med Phys; 1998 Dec; 25(12):2269-70. PubMed ID: 9874817
[No Abstract] [Full Text] [Related]
20. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy.
Andrzejewski P; Kuess P; Knäusl B; Pinker K; Georg P; Knoth J; Berger D; Kirisits C; Goldner G; Helbich T; Pötter R; Georg D
Radiother Oncol; 2015 Dec; 117(3):509-14. PubMed ID: 26349588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
